Atara Biotherapeutics Inc... (ATRA)
6.50
-0.38 (-5.52%)
At close: Mar 28, 2025, 3:59 PM
Atara Biotherapeutics Balance Sheet Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Cash & Equivalents | 25.03M | 25.84M | 92.94M | 106.08M | 200.4M | 74.32M | 60.7M | 79.22M | 47.97M | 23.75M | 21.9M | 51.62M | 4.21M |
| Short-Term Investments | 17.47M | 25.88M | 149.88M | 264.98M | 300.25M | 184.79M | 248.93M | 86.87M | 207.71M | 296.74M | 82.22M | n/a | n/a |
| Long-Term Investments | n/a | n/a | n/a | 1.2M | 1.2M | 1.2M | 1.2M | 1.2M | n/a | n/a | n/a | n/a | n/a |
| Other Long-Term Assets | 3.1M | 4.84M | 7.02M | 2.37M | 827K | 567K | 574K | 260K | 102K | 108K | 48K | 12K | 39K |
| Receivables | 1.48M | 34.11M | 40.22M | 986K | 1.25M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Inventory | 10.65M | 9.71M | 1.59M | 1.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Current Assets | 10.26M | 6.33M | 10.45M | 12.57M | 21.36M | 13.88M | 11.86M | 6.09M | 4.87M | 4.12M | 3.82M | 193K | 35K |
| Total Current Assets | 64.89M | 101.87M | 295.08M | 384.62M | 523.27M | 272.99M | 321.49M | 172.19M | 260.55M | 324.6M | 106.03M | 51.81M | 4.24M |
| Property-Plant & Equipment | 41.1M | 58.79M | 74.32M | 79.94M | 62.82M | 68.18M | 68.58M | 44.13M | 3.26M | 270K | 48K | 8K | 9K |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 44.2M | 63.63M | 81.34M | 83.51M | 64.85M | 69.95M | 70.35M | 45.59M | 3.36M | 378K | 96K | 20K | 48K |
| Total Assets | 109.1M | 165.5M | 376.42M | 468.13M | 588.12M | 342.94M | 391.84M | 217.78M | 263.91M | 324.98M | 106.12M | 51.83M | 4.29M |
| Account Payables | 4.37M | 3.68M | 6.87M | 17.37M | 7.12M | 7.96M | 3.72M | 14.71M | 2.78M | 1.45M | 1K | 155K | 121K |
| Deferred Revenue | 95.09M | 77.83M | 8M | 40.76M | 33.45M | 21.47M | -490K | -500K | n/a | n/a | n/a | n/a | n/a |
| Short-Term Debt | n/a | 12.18M | 13.64M | 2.75M | 1.99M | 1.58M | 587K | 500K | n/a | n/a | n/a | n/a | n/a |
| Other Current Liabilities | 35.12M | 48.53M | 50.41M | 44.91M | 40.34M | 27.2M | 35.67M | 12.44M | 6.9M | 8.26M | 2.72M | 1.21M | 1.17M |
| Total Current Liabilities | 134.57M | 142.23M | 78.92M | 105.79M | 82.9M | 36.74M | 39.98M | 27.65M | 9.68M | 9.71M | 2.72M | 1.52M | 1.3M |
| Long-Term Debt | 29.91M | 45.69M | 58.06M | 25.52M | 13.04M | 14.14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Long-Term Liabilities | 41.89M | 39.25M | 35.8M | 1.5M | 2.04M | 1.28M | 13M | 12.27M | 503K | 166K | 216K | 61.32M | 6.71M |
| Total Long-Term Liabilities | 71.81M | 122.51M | 170.86M | 82.73M | 42.88M | 15.42M | 13M | 12.27M | 503K | 166K | 216K | 61.32M | 6.71M |
| Total Liabilities | 206.38M | 264.74M | 249.78M | 188.51M | 125.78M | 52.16M | 52.98M | 39.91M | 10.18M | 9.88M | 2.94M | 62.84M | 8.02M |
| Total Debt | 29.91M | 57.87M | 71.7M | 25.52M | 13.04M | 14.14M | 738K | 500K | n/a | n/a | n/a | n/a | n/a |
| Common Stock | 1K | 11K | 10K | 9K | 8K | 6K | 5K | 3K | 3K | 3K | 2K | 1K | 1K |
| Retained Earnings | -2.05B | -1.97B | -1.69B | -1.46B | -1.12B | -817.96M | -527.35M | -296.65M | -177.16M | -98.11M | -40.89M | -12.88M | -4.11M |
| Comprehensive Income | 8K | -204K | -2.07M | -368K | 296K | 220K | -340K | -151K | -183K | -518K | -100K | -335K | -6.71M |
| Shareholders Equity | -97.28M | -99.23M | 126.64M | 279.61M | 462.34M | 290.78M | 338.86M | 177.86M | 253.74M | 315.1M | 103.18M | -11.02M | -3.73M |
| Total Investments | 17.47M | 25.88M | 149.88M | 264.98M | 300.25M | 184.79M | 248.93M | 86.87M | 207.71M | 296.74M | 82.22M | n/a | n/a |